For the full year, Vertex guided for revenue between $11.75 billion and $12 billion, which includes the U.S. launch of cystic fibrosis treatment for patients aged six and older Alyftrek and early ...
Hosted on MSN54m
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top EstimatesBiotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results , with sales up 15.7% year on year to $2.91 billion. The company expects the full year’s revenue to be around $11.88 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback